Solid Biosciences (NASDAQ: SLDB) CMO granted options and sells shares

Rhea-AI Filing Summary

Solid Biosciences Inc. Chief Medical Officer Gabriel Brooks reported multiple equity compensation events and a related stock sale. On January 29, 2026, 58,847 performance stock units vested into common stock after a performance milestone was certified as achieved, increasing his holdings before later transactions.

That same day, he received an option to buy 207,450 shares at an exercise price of $6.60 per share, vesting over four years, and 103,750 restricted stock units that also vest over four years in 25% annual installments. On January 31, 2026, 28,225 restricted stock units from a 2025 grant vested into common stock.

On February 2, 2026, Brooks sold 28,335 shares of common stock at a weighted average price of $6.4369 per share to cover withholding taxes after PSU vesting under a pre-arranged automatic sell-to-cover instruction. Following these transactions, he directly held 96,708 shares of Solid Biosciences common stock.

Insider Trade Summary

Net Seller: 28,335 shares ($182,390)

Net Sell 7 txns

Insider Brooks Gabriel

Role Chief Medical Officer

Sold 28,335 shs ($182K)

Type	Security	Shares	Price	Value
Sale	Common Stock	28,335	$6.4369	$182K
Exercise	Restricted Stock Units	28,225	$0.00	--
Exercise	Common Stock	28,225	$0.00	--
Exercise	Performance Stock Units	58,847	$0.00	--
Grant/Award	Employee Stock Option (Right to Buy)	207,450	$0.00	--
Grant/Award	Restricted Stock Units	103,750	$0.00	--
Exercise	Common Stock	58,847	$0.00	--

Holdings After Transaction: Common Stock — 96,708 shares (Direct); Restricted Stock Units — 84,675 shares (Direct); Performance Stock Units — 0 shares (Direct); Employee Stock Option (Right to Buy) — 207,450 shares (Direct)

Footnotes (1)

1. Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis (the "PSUs"). Includes 4,152 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on November 28, 2025. Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis. This sale was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Dr. Brooks on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Brooks. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.295 to $6.580, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form. The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares. This option was granted on the 2026 Grant Date and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary. The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary. On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 112,900 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brooks Gabriel

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MA 02129

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/29/2026		M		58,847	A	(1)	96,818(2)	D
Common Stock	01/31/2026		M		28,225	A	(3)	125,043	D
Common Stock	02/02/2026		S		28,335(4)	D	$6.4369(5)	96,708	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Stock Units	(1)	01/29/2026		M			58,847	(6)	(6)	Common Stock	58,847	$0.00	0	D
Employee Stock Option (Right to Buy)	$6.6	01/29/2026		A		207,450		(7)	01/29/2036	Common Stock	207,450	$0.00	207,450	D
Restricted Stock Units	(3)	01/29/2026		A		103,750		(8)	(8)	Common Stock	103,750	$0.00	103,750	D
Restricted Stock Units	(3)	01/31/2026		M			28,225	(9)	(9)	Common Stock	28,225	$0.00	84,675	D

Explanation of Responses:

1. Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis (the "PSUs").

2. Includes 4,152 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on November 28, 2025.

3. Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis.

4. This sale was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Dr. Brooks on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Brooks.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.295 to $6.580, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.

6. The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares.

7. This option was granted on the 2026 Grant Date and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary.

8. The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary.

9. On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 112,900 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary.

	/s/ Kimberly Cornwell as attorney-in-fact for Gabriel Brooks	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did SLDB Chief Medical Officer Gabriel Brooks report?

Gabriel Brooks reported PSU vesting into 58,847 common shares, new grants of 207,450 stock options and 103,750 RSUs, additional RSU vesting of 28,225 shares, and a 28,335-share sale to cover taxes. All transactions involved Solid Biosciences common stock or related equity awards.

How many stock options and RSUs did the SLDB CMO receive in January 2026?

On January 29, 2026, the CMO received options for 207,450 shares at a $6.60 exercise price and 103,750 restricted stock units. Both awards vest over four years, with 25% vesting after one year and the remainder vesting in equal periodic installments through the fourth anniversary.

Why did Gabriel Brooks sell 28,335 SLDB shares and at what price?

He sold 28,335 Solid Biosciences shares on February 2, 2026 at a weighted average price of $6.4369 per share. According to the filing, the sale covered withholding taxes after PSU vesting under a durable automatic sell-to-cover instruction, not a discretionary trade.

What performance milestone triggered PSU vesting for the SLDB CMO?

The first performance milestone, tied to non-market, non-financial business objectives, was certified as met on January 29, 2026. This determination caused 25% of the target performance stock units, representing 58,847 underlying shares, to vest and convert into Solid Biosciences common stock for the CMO.

How do Gabriel Brooks’s SLDB PSUs and RSUs convert into common stock?

Each performance stock unit and restricted stock unit converts to Solid Biosciences common stock on a one-for-one basis. PSU vesting depends on Board-certified performance milestones, while RSUs vest over time in scheduled annual or monthly installments, then settle in an equal number of common shares.

What were Gabriel Brooks’s Solid Biosciences share holdings after these transactions?

After the reported January and February 2026 transactions, Brooks directly held 96,708 shares of Solid Biosciences common stock. This figure reflects PSU and RSU conversions into shares, the new equity grants, and the 28,335-share sale executed to satisfy tax withholding obligations.